Article

Educated Patient® Lung Cancer Summit Advancements in Early-Stage NSCLC Presentation: April 29, 2023

Author(s):

Brielle Benyon

Watch Dr. Erminia Massarelli, from City of Hope National Medical Center, discuss advancements in early-stage non-small cell disease during the CURE® Educated Patient® Lung Cancer Summit.

Recent years have brought new treatments — both in the pre- and post-surgical setting — for patients with early-stage non-small cell lung cancer, explained Dr. Erminia Massarelli.

“In the last few years, we have had pretty interesting developments and approval of different drugs in early stage non-small cell lung cancer,” Massarelli, an associate professor in the Department of Medical Oncology and Therapeutics Research and division chief of thoracic surgery at City of Hope National Medical Center, said at the CURE® Educated Patient® Lung Cancer Summit. “So we call adjuvant therapy when it follows surgical resection of the tumor and your adjuvant therapy when actually we do systemic therapy before the surgical resection of the tumor.”

Neoadjuvant Treatment

Before patients undergo surgery to remove their cancer, they may receive neoadjuvant treatment, which is therapy designed to shrink tumors before they are removed to increase the likelihood of cure.

In this setting, patients may receive chemotherapy, immunotherapy and/or targeted therapy — each either alone or as a single-agent. Of note, a clinical trial showed that the immunotherapy drug, Opdivo (nivolumab) improved survival outcomes for patients with stage 1B-3A non-small cell lung cancer when given within six week before surgery. Based on those findings, the Food and Drug Administration (FDA) approved the treatment in that setting.

“It’s important to really attack the non-small cell lung cancer when it’s early on, when there is still an option of cure,” Massarelli said.

Looking ahead, a clinical trial is investigating the use of Tagrisso (Osimertinib) either alone or in combination with chemotherapy for neoadjuvant treatment of patients with EGFR-mutant non-small cell lung cancer.

Adjuvant Treatment

The goal of post-surgical treatment (also known as adjuvant treatment) is to decrease the risk of cancer recurrence, Massarelli said.

Research has shown that Tecentriq (atezolizumab) tends to improve survival outcomes over chemotherapy for stage 2-3A disease that has been surgically removed and is PD-L1 positive, meaning that the cancer cells express the PD-L1 protein, which Tecentriq targets. As such, the immunotherapy drug is FDA-approved in this setting.

Keytruda (pembrolizumab) is also approved for patients with stage 1B, 2 and 3 surgically resected non-small cell lung cancer, regardless of PD-L1 status, as the checkpoint inhibitor showed improved disease-free survival (time a patient lives after treatment without signs or symptoms of cancer) compared with placebo.

Additionally, Tagrisso is approved for the post-surgical treatment of patients with EGFR exon19-deletion stage 1-3 non-small cell lung cancer.

“In conclusion, as of today, early-stage non-small cell lung cancer can actually be effectively cured,” Massarelli said. “We are increasing more and more the chances of cure either giving treatment before surgery or actually giving treatment following surgery.”

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Image of a man in a suit.
Image of woman with brown hair.
Image of a man with short black hair.
Image of a woman with wavy blonde hair wearing glasses.
Image of man with black hair.
Image of a woman with layered hair, wearing a bright blue cardigan.
Image of a man with short black hair.
Image of man with gray hair.
Image of woman with black hair.
Related Content
Subcutaneous Keytruda plus berahyaluronidase alfa meets phase 3 trial end points in non–small cell lung cancer.
November 21st 2024

Subcutaneous Keytruda Plus Berahyaluronidase Alfa Combo Meets Phase 3 Trial End Points in NSCLC

Ryan Scott
Treatment with subcutaneous Keytruda plus berahyaluronidase alfa meets phase 3 trial end points in the treatment of metastatic non–small cell lung cancer.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Image of a woman with short blonde hair, wearing a colorful striped shirt.
November 19th 2024

Why Clinical Trials Don’t Have to Be Patients’ ‘Last Line of Defense’

Alex Biese
A patient with small cell lung cancer shared her clinical trial experience with CURE® and how she encourages other patients with cancer to enroll.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Blue background with the FDA logo.
November 16th 2024

FDA Receives Application for Dato-DXd Treatment in EGFR-Mutated NSCLC

Ryan Scott
For patients with previously treated EGFR-mutated NSCLC, a new BLA has been submitted to the FDA seeking the accelerated approval of Dato-DXd.
Illustration of lungs.
November 15th 2024

Anti-TIGIT Therapy-Based Treatment Combo Did Not Improve Survival in Extensive-Stage SCLC

Caroline Seymour
The anti-TIGIT therapy, vibostolimab, plus Keytruda and chemotherapy did not improve overall survival versus Tecentriq plus chemotherapy in extensive-stage small cell lung cancer.